|Bid||0.00 x 1000|
|Ask||0.00 x 1100|
|Day's Range||61.98 - 64.32|
|52 Week Range||30.79 - 64.62|
|Beta (5Y Monthly)||1.18|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 01, 2021 - Mar 05, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||61.58|
PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced the initiation of the registration-directed Phase 3 MOVE-FA study evaluating vatiquinone (PTC743) in children and young adults with Friedreich ataxia (FA). FA is a genetic, progressive, neurodegenerative movement disorder, typically diagnosed in childhood or adolescence.1 PTC estimates that there are 25,000 patients with FA worldwide and there are currently no approved disease modifying therapies for FA. In a previous Phase 2 trial, vatiquinone demonstrated a statistically significant effect on disease severity at 24 months relative to age and stage-matched natural history controls as assessed by the validated Friedreich ataxia rating scale (FARS) score and a favorable safety profile. Vatiquinone has been granted Orphan Drug Designation and Fast Track Designation for Friedreich ataxia by the U.S. Food and Drug Administration (FDA).
This article will reflect on the compensation paid to Stuart Peltz who has served as CEO of PTC Therapeutics, Inc...
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at Evercore ISI 3rd Annual HealthCONx Conference on Tuesday, December 1st at 11:45 a.m. ET.